NASDAQ:AMGN Amgen (AMGN) Stock Price, News & Analysis $336.50 +3.58 (+1.08%) (As of 11:16 AM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Amgen Stock (NASDAQ:AMGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Key Stats Today's Range$334.61▼$338.7050-Day Range$312.50▼$335.9752-Week Range$249.70▼$346.85Volume389,663 shsAverage Volume2.49 million shsMarket Capitalization$180.51 billionP/E Ratio48.07Dividend Yield2.67%Price Target$327.28Consensus RatingHold Company OverviewAmgen Inc. is a multinational biopharmaceutical company headquartered in Thousand Oaks, California. Established in 1980 by William Bowes from Cetus Corporation and Winston Salser from UCLA, Amgen is now one of the world's largest independent biotechnology companies, with over 24,000 employees worldwide. The company's primary focus is on molecular biology and biochemistry, intending to provide healthcare solutions based on recombinant DNA technology.Neulasta, one of Amgen's most prominent selling product lines, is used to prevent infections in patients undergoing cancer chemotherapy. Enbrel is another famous selling product line for Amgen, used in the treatment of rheumatoid arthritis and other autoimmune diseases. The company's other products have various applications in treating cancer, anemia, osteoporosis and other conditions.Amgen has a rich history of strong leadership, with the appointment of several successful CEOs since its inception. Robert A. Bradway is the current CEO and was brought to Amgen in May 2012 following his predecessor's retirement. Bradway has led the company to new heights with strategic acquisitions and partnerships.Amgen has made at least five major corporate acquisitions. In 2019, the company announced it would acquire Nuevolution AB and the Otezla drug program from Celgene and a 20.5% stake in the Beijing-based BeiGene for $2.7 billion. These acquisitions have strengthened Amgen's drug pipeline and provided new revenue streams for the company. In March 2021, Amgen announced its plans to acquire Five Prime Therapeutics and its lead research drug candidate, bemarituzumab, for $1.9 billion. It also agreed to acquire Rodeo Therapeutics for up to $720 million. These acquisitions are part of the company's ongoing efforts to expand its drug pipeline and bring new treatments to patients.In 2012, Amgen faced legal issues when it pleaded guilty and agreed to pay $150 million in criminal penalties and $612 million in damages to resolve 11 related whistleblower complaints. Amgen has also faced criticism for lobbying for a two-year extension on sales of drugs, including Sensipar, without government controls, which will cost taxpayers an estimated $500 million. However, the company remains committed to providing innovative and effective healthcare solutions for patients.Amgen's success can be attributed to its commitment to innovation, strategic acquisitions, strong partnerships and top-end leadership. The company's impressive portfolio of products and its commitment to the community has solidified Amgen's position as a leader in biopharmaceuticals.Written by Jeffrey Neal JohnsonRead More… China Stockpiling Gold “Like No Tomorrow” (Ad)For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a population of over 1.4 BILLION is “buying gold like there’s no tomorrow,” according to The New York Times. China, a rising global economic threat, aims to reduce its dependence on the US dollar… . Click here now to get your free 'De-Dollarization' Guide. Amgen Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 91st PercentileAmgen scored higher than 91% of companies evaluated by MarketBeat, and ranked 110th out of 1,007 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.2 / 5Analyst RatingHold Consensus RatingAmgen has received a consensus rating of Hold. The company's average rating score is 2.48, and is based on 10 buy ratings, 11 hold ratings, and no sell ratings.Amount of Analyst CoverageAmgen has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Amgen's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth5.28% Earnings GrowthEarnings for Amgen are expected to grow by 5.28% in the coming year, from $19.49 to $20.52 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amgen is 48.27, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 139.51.Price to Earnings Ratio vs. SectorThe P/E ratio of Amgen is 48.27, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 147.31.Price to Earnings Growth RatioAmgen has a PEG Ratio of 2.93. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAmgen has a P/B Ratio of 29.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Amgen's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.58% of the float of Amgen has been sold short.Short Interest Ratio / Days to CoverAmgen has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Amgen has recently decreased by 8.23%, indicating that investor sentiment is improving significantly. Dividend3.3 / 5Dividend StrengthStrong Dividend YieldAmgen pays a meaningful dividend of 2.73%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthAmgen has been increasing its dividend for 13 years.Dividend CoverageThe dividend payout ratio of Amgen is 128.57%. Payout ratios above 75% are not desirable because they may not be sustainable.Dividend SustainabilityBased on earnings estimates, Amgen will have a dividend payout ratio of 43.86% next year. This indicates that Amgen will be able to sustain or increase its dividend.Read more about Amgen's dividend. Sustainability and ESG3.9 / 5Environmental Score-2.42 Percentage of Shares Shorted1.58% of the float of Amgen has been sold short.Short Interest Ratio / Days to CoverAmgen has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Amgen has recently decreased by 8.23%, indicating that investor sentiment is improving significantly. News and Social Media1.4 / 5News Sentiment0.60 News SentimentAmgen has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for Amgen this week, compared to 20 articles on an average week.Search InterestOnly 32 people have searched for AMGN on MarketBeat in the last 30 days. This is a decrease of -26% compared to the previous 30 days.MarketBeat FollowsOnly 15 people have added Amgen to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Amgen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.69% of the stock of Amgen is held by insiders.Percentage Held by Institutions76.50% of the stock of Amgen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Amgen's insider trading history. AMGN Stock News HeadlinesBoogers, Biotech and Health Insurance: The Safest Dividends for a RecessionLet’s talk about recession-resistant dividends because, if history is any guide, we are certainly “on the clock” for a slowdown if not already in one.August 27, 2024 | marketbeat.comEli Lilly’s Path to the Next Trillion Market Capitalization (AMGN)Eli Lilly and Co. (NYSE: LLY) is a pharmaceutical giant that's made headlines for its GLP-1/GIP weight loss drug Tirzepatide, aka Mounjaro, for Type 2 diabetes.August 26, 2024 | marketbeat.com⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.September 19, 2024 | Behind the Markets (Ad)Amgen (AMGN) Gets a Buy from JefferiesSeptember 18 at 10:17 AM | markets.businessinsider.comAmgen Inc. (AMGN): A Bull Case TheorySeptember 17 at 12:51 PM | insidermonkey.comAmgen Inc. (NASDAQ:AMGN) Short Interest Down 8.2% in AugustSeptember 17 at 5:07 AM | americanbankingnews.comAMGN Sep 2024 275.000 callSeptember 16 at 5:41 PM | ca.finance.yahoo.comAMGN Sep 2024 275.000 putSeptember 16 at 5:41 PM | ca.finance.yahoo.comSee More Headlines AMGN Stock Analysis - Frequently Asked Questions How have AMGN shares performed this year? Amgen's stock was trading at $288.02 at the start of the year. Since then, AMGN stock has increased by 17.3% and is now trading at $337.87. View the best growth stocks for 2024 here. How were Amgen's earnings last quarter? Amgen Inc. (NASDAQ:AMGN) released its quarterly earnings results on Tuesday, August, 6th. The medical research company reported $4.97 EPS for the quarter, missing analysts' consensus estimates of $5.01 by $0.04. The company's quarterly revenue was up 20.1% compared to the same quarter last year. Read the conference call transcript. Does Amgen have any subsidiaries? Amgen subsidiaries include these companies: TeneoBio, Five Prime Therapeutics, Rodeo Therapeutics, Otezla, Nuevolution, Catherex, Catherex, and others. Who are Amgen's major shareholders? Top institutional shareholders of Amgen include Primecap Management Co. CA (2.69%), Bank of New York Mellon Corp (1.00%), Legal & General Group Plc (0.90%) and Dimensional Fund Advisors LP (0.50%). Insiders that own company stock include Amgen Inc, Murdo Gordon, Jonathan P Graham, Robert Eckert, Nancy A Grygiel, Nancy A Grygiel and R Sanders Williams. View institutional ownership trends. How do I buy shares of Amgen? Shares of AMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Amgen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amgen investors own include Johnson & Johnson (JNJ), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV) and Walt Disney (DIS). Company Calendar Last Earnings8/06/2024Dividend Payable8/06/2024Ex-Dividend for 8/6 Dividend8/16/2024Today9/19/2024Next Earnings (Estimated)10/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:AMGN CUSIP03116210 CIK318154 Webwww.amgen.com Phone(805) 447-1000Fax805-447-1010Employees26,700Year Founded1980Price Target and Rating Average Stock Price Target$327.28 High Stock Price Target$381.00 Low Stock Price Target$235.00 Potential Upside/Downside-1.7%Consensus RatingHold Rating Score (0-4)2.48 Research Coverage21 Analysts Profitability EPS (Most Recent Fiscal Year)$7.00 Trailing P/E Ratio47.56 Forward P/E Ratio17.08 P/E Growth2.93Net Income$6.72 billion Net Margins10.12% Pretax Margin11.40% Return on Equity161.72% Return on Assets10.81% Debt Debt-to-Equity Ratio9.64 Current Ratio1.26 Quick Ratio0.89 Sales & Book Value Annual Sales$30.93 billion Price / Sales5.77 Cash Flow$26.59 per share Price / Cash Flow12.52 Book Value$11.65 per share Price / Book28.58Miscellaneous Outstanding Shares536,435,000Free Float532,734,000Market Cap$178.59 billion OptionableOptionable Beta0.61 Social Links Should I Buy Amgen Stock? AMGN Pros and Cons Explained These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, September 11, 2024. Please send any questions or comments about these Amgen pros and cons to contact@marketbeat.com. Amgen Bull Case Here are some ways that investors could benefit from investing in Amgen Inc.: Amgen Inc. has a strong track record of developing and delivering human therapeutics worldwide, indicating a stable and reliable business model. Recent analysts' ratings have been positive, with an average rating of "Moderate Buy" and an average price target of $326.89, suggesting growth potential. Amgen Inc. announced a quarterly dividend of $2.25 per share, providing investors with a steady income stream and a dividend yield of 2.72%. Amgen Inc.'s stock price has been trading at $331.01, showing an upward trend and potential for capital appreciation. Amgen Inc. reported strong quarterly earnings, with an EPS of $4.97 and revenue of $8.39 billion, demonstrating financial stability and growth. Amgen Bear Case Investors should be bearish about investing in Amgen Inc. for these reasons: Amgen Inc. has a high debt-to-equity ratio of 11.96, which may indicate increased financial risk and potential limitations on future growth. The company's P/E ratio of 47.29 and P/E/G ratio of 2.78 suggest that the stock may be overvalued compared to its growth prospects. Amgen Inc.'s beta of 0.58 indicates lower volatility compared to the market, potentially limiting short-term trading opportunities for investors. Despite positive analyst ratings, there are concerns about the company's ability to sustain its growth momentum in the face of increasing competition in the biopharmaceutical industry. Amgen Inc.'s 50-day and 200-day moving averages of $324.06 and $300.22, respectively, may signal potential price volatility and uncertainty in the near term. This page (NASDAQ:AMGN) was last updated on 9/19/2024 by MarketBeat.com Staff From Our PartnersBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start ...Greenlane | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding Amgen Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Amgen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.